铜绿假单胞菌注射液对难治性气胸的疗效评价  

Therapeutic Evaluation of PA-MSHA in the Treatment of Refractory Pneumothorax

作　　者：吴汉生[1] 王伟森[1] 肖大伟[1] 陈淑贤[2] WU Han-sheng;WANG Wei-sheng;XIAO Da-wei;CHEN Su-xian(Department of Cardiothoracic Surgery,the First Affiliated Hospital of Shantou University Medical College,Shantou 515041, China;Department of Respiratory Medicine,the First Affiliated Hospital of Shantou University Medical College,Shantou 515041,China)

机构地区：[1]汕头大学医学院第一附属医院心胸外科,广东汕头515041 [2]汕头大学医学院第一附属医院呼吸内科,广东汕头515041

出　　处：《汕头大学医学院学报》2018年第4期224-226,共3页Journal of Shantou University Medical College

基　　金：汕头市医疗科技计划项目(汕府科[2015]123号-37)

摘　　要：目的:对难治性气胸患者胸腔注入铜绿假单胞菌注射液,并评价其治疗效果。方法:回顾性选取79例难治性气胸患者,随机分为对照组(40例,保守治疗)和观察组(39例,胸腔注入铜绿假单胞菌注射液),比较两组疗效。结果:观察组与对照组治愈率无明显统计差异(P> 0.05),但住院时间、复发率及费用明显低于对照组(P <0.05)。结论:胸腔注入铜绿假单胞菌注射液对难治性气胸的明显疗效,安全可靠,且住院时间及费用低。Objective: To evaluate the effect of injection of pseudomonas aeruginosa-mannose-sensitive Hemagglutinin(PA-MSHA) into pleural cavity of patients with refractory pneumothorax. Methods: 79 patients with refractory pneumothorax were randomly divided into control group(conservative treatment) and observation group(chest injection of PA-MSHA). Results: There was no statistical difference in cure rate between observation group and control group(P > 0.05), but the average length of stay(A LOS), recurrence rate and the cost of the observation group were significantly lower than the control group(P < 0.05). Conclusion:Using PA-MSHA in the treatment of refractory pneumothorax is safe reliable and lower both the A LOS and cost.

关 键 词：铜绿假单胞菌注射液 难治性气胸 胸腔闭式引流 

分 类 号：R561.4[医药卫生—呼吸系统] R969.4[医药卫生—内科学]